The Black Box Came Off Menopause Hormone Therapy. Here's What That Actually Means.

For 23 years, menopause hormone therapy carried the same kind of warning label the FDA reserves for chemotherapy drugs. A black-bordered box on every package told women that estrogen could raise their risk of breast cancer, heart attack, stroke, and dementia. Many women — and many doctors — read that label and decided the safer choice was to do nothing.

In February 2026, that label changed.

The U.S. Food and Drug Administration formally removed the broad “black box” warning from menopause hormone therapy products containing estrogen. The announcement was first made on November 10, 2025 by HHS and the FDA, and the updated labeling went into effect in early 2026. It was the largest regulatory shift in menopause care in more than two decades.

If you have heard about this change in passing — on TikTok, in a news headline, from a friend — and you are wondering what is actually different, this is the plain-language version. We will cover what was removed, what stayed, why the warning was there in the first place, and the questions worth bringing to your next consult.

The FDA withdrew “black box” warnings for cardiovascular disease, breast cancer, and probable dementia from FDA-approved menopause hormone therapy products in February 2026. The endometrial cancer warning remains in place for women with a uterus who take systemic estrogen alone — which is why a progestogen is co-prescribed. New labels add age-specific language reinforcing the “10-year window”: women who start hormone therapy within 10 years of menopause and before age 60 may see net benefit. The change does not apply to compounded “bioidentical” products, which are regulated differently.

To understand what changed, it helps to know what the warning was responding to.

In 2002, the Women’s Health Initiative (WHI) — the largest study of menopause hormone therapy ever conducted — published its first results. The study had enrolled more than 16,000 women on combined estrogen plus progestin and another 10,000 on estrogen alone. Researchers stopped the combined-hormone arm early because they found an increased risk of invasive breast cancer, pulmonary embolism, and stroke. The estrogen-only arm showed an elevated stroke risk.

The headlines were dramatic. In the year that followed, U.S. hormone therapy prescriptions dropped sharply. In 2003, the FDA added a black box warning to estrogen-containing menopause products, citing risks of cardiovascular disease, breast cancer, and probable dementia. That warning stayed on the label for 23 years.

What the original WHI study did not fully convey — and what later re-analyses spent two decades clarifying — was that the women in the trial were, on average, more than 12 years past menopause when they started hormones, with an average age of 63. The harm signal was concentrated in older women who started therapy long after their last menstrual period. Subsequent analyses of women who began hormone therapy within 10 years of menopause and under age 60 told a different story: in that group, the cardiovascular and mortality data trended favorable, not unfavorable.

The medical community recognized this nuance long before the label did. The Menopause Society, the American College of Obstetricians and Gynecologists, the Endocrine Society, and most international menopause organizations all updated their guidance over the 2010s and 2020s to reflect the “timing hypothesis.” The FDA label took longer to follow.

The February 2026 label change affects four categories of menopause hormone therapy products:

• Combined estrogen and progestogen systemic therapy (oral and transdermal)
• Systemic estrogen-alone therapy
• Systemic progestogen-alone therapy
• Low-dose vaginal estrogen products

The warnings the FDA withdrew, in plain terms:

1. Cardiovascular disease. The blanket warning that hormone therapy increases cardiovascular risk has been removed. Newer evidence — including a large 2023 trial called TRAVERSE on the male hormone side and decades of WHI re-analyses on the female side — supports the conclusion that timing matters enormously, and that risk in healthy women initiating within the 10-year window is not what the original label suggested.

2. Breast cancer. The broad “increases breast cancer risk” boxed warning has been withdrawn. This does not mean breast cancer risk is zero. It means the relationship is more nuanced than a single label could capture — duration of use, type of hormone, progestogen formulation, baseline risk, and age at initiation all matter, and patients deserve an individualized conversation rather than a blanket warning.

3. Probable dementia. The dementia warning, which had been based largely on the older subgroup of the WHI Memory Study (WHIMS) — women who started hormones in their late 60s and 70s — has been removed. Research on estrogen’s potential role in brain aging is active and unresolved, but the data did not support a population-wide warning when therapy is initiated near menopause.

One warning was not removed: endometrial cancer, for women with a uterus who take systemic estrogen alone.

This is a long-standing finding with a clear mechanism. Estrogen by itself stimulates the lining of the uterus; without a progestogen to balance it, that stimulation can lead to abnormal cell growth. This is why women who still have their uterus and who are prescribed systemic estrogen are also prescribed a progestogen — or use a hormonal IUD that delivers progestin locally. Women who have had a hysterectomy are typically prescribed estrogen alone, because the endometrium isn’t there to protect.

The retained warning is a useful reminder, not a contradiction of the broader change. It means: estrogen plus progestogen for women with a uterus; estrogen alone is reasonable after hysterectomy. The clinical practice was already this; the label simply reflects it.

The most consequential addition to the new label is age-specific guidance. Updated labeling notes that women who initiate menopause hormone therapy within 10 years of menopause onset, and before age 60, may experience long-term health benefits in addition to symptom relief.

This is the “timing hypothesis,” and it is the single most important concept to understand if you are deciding whether hormone therapy is right for you. The data suggest:

• Within the window (within 10 years of last period, under 60) — the balance of evidence leans toward net benefit for symptomatic women: bone protection, cardiovascular neutrality or modest benefit, symptom relief, and possibly favorable effects on metabolic health.
• Outside the window (10+ years post-menopause, or starting in the late 60s and beyond) — the calculus shifts. Cardiovascular and stroke risk become more salient. Therapy can still be appropriate, but it requires a more detailed risk assessment.

Note what this is not saying. It is not saying every woman within the window should take hormones. It is saying that for women who want to consider hormone therapy and who fall within that window, the historical fear created by the old label is not well supported by the data, and the conversation should be individualized rather than reflexively avoided.

Some things have not changed and are worth saying plainly:

• Hormone therapy is still a prescription medication with real considerations. Personal and family history of breast cancer, venous thromboembolism, active liver disease, unexplained vaginal bleeding, and certain cardiovascular conditions all factor into candidacy.
• Compounded “bioidentical” hormone products — particularly subcutaneous pellets prepared by compounding pharmacies — are not FDA-approved. The 2026 label change applies to FDA-approved products. The American College of Obstetricians and Gynecologists’ November 2023 Clinical Consensus continues to advise against routine prescription of compounded bioidentical menopausal hormone therapy as a default. There is a place for compounded therapy in specific clinical situations, but it should be a deliberate choice with informed consent, not the standard option.
• Hormone therapy is not approved by the FDA for prevention of dementia, heart disease, or osteoporosis as standalone indications. It is approved for moderate to severe vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause, with bone protection as an additional indication for women who are also candidates for it.
• Individual decisions still require a clinician who knows your history. The label change makes the conversation more honest. It does not replace the conversation.

If you have been on the fence about hormone therapy — or if you went off it years ago because of the old warning — these are the questions a thoughtful clinician will be ready to discuss:

• Am I within the 10-year window for initiation, and what does that mean for me specifically given my baseline risk factors?
• If I am a candidate, which formulation is right for me — transdermal patch, oral tablet, vaginal estrogen for localized symptoms — and why?
• What progestogen is being recommended if I have a uterus, and what is the evidence for that specific formulation?
• What labs and screening should I have before starting — mammogram, baseline labs, blood pressure, lipid panel?
• How will we monitor and re-evaluate, and what is the long-term plan?
• Are there non-hormonal options that should be considered first or alongside, including for sleep, mood, and bone health?

The answers will be different for every woman. That is the point.

At Naya Wellness, our nurse practitioner team has always treated hormone therapy decisions as individual conversations — labs, full medical history, careful informed consent, and follow-up that catches what a single appointment cannot. The FDA’s 2026 update does not change our process. It does change the starting point of the conversation: many women who were told for two decades that hormone therapy was too risky to even consider can now have an honest, evidence-based discussion about whether it is right for them.

We offer bioidentical hormone replacement therapy consults at our Chatsworth and Santa Barbara clinics, and via telehealth across California. The first step is a thorough intake — symptoms, history, goals, contraindications, and labs — and a treatment plan that may include hormones, may include non-hormonal therapies, and is always reviewed with you in plain language.

Two California locations and statewide telehealth — click a card to view details and book.